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Abstract: 
Neo-epitopes are emerging as attractive targets for cancer immunotherapy and new 
strategies for rapid identification of relevant candidates have become a priority. We 
propose a method for in silico selection of candidates which have a high potential for 
neo-antigen generation and are likely to appear in multiple patients. This is achieved 
by carefully screening 33 TCGA data sets for recurrent somatic amino acid exchanges 
and, for the 1,055 resulting recurrent variants, applying MHC class I binding prediction 
algorithms. A preliminary confirmation of epitope binding and recognition by CD8 T 
cells has been carried out for a couple of candidates in humanized mice. Recurrent 
neo-epitopes may be suitable to supplement existing personalized T cell treatment 
approaches with precision treatment options.
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Introduction
Increasing evidence suggests that clinical efficacy of cancer immunotherapy is driven 
by T cell reactivity against neo-antigenes (1, 2, 3, 4). For tumors with no viral etiology 
these neo-antigenes are created either by aberrant expression of genes normally 
restricted to immuno-privileged tissues, or by tumor specific DNA alterations that 
result in the formation of novel protein sequences. 
While not yet fully understood, immune response to any mutated peptide sequence 
and recognition of tumor cells containing this peptide depends critically on the ability 
of the MHC class I complexes to bind to the mutated peptide in order to present it to a 
T cell (5). A variety of machine learning algorithms have been developed to determine 
the MHC binding in silico, see (6) for review. Most methods are trained on Immune 
Epitope Database (IEDB) (7) entries and use allele specific predictors for frequent 
alleles, while pan-methods are applied to extrapolate to less common alleles. 
With the advent of affordable short read sequencing comprehensive neo-antigen 
screening based on whole exome sequencing has become feasible and many cancer 
immune therapeutic approaches try to utilize detailed understanding of the neo-
epitope spectrum to create additional or boost pre-existing T cell reactivity for 
therapeutic purposes (8, 9). However, in practice the selection and validation of the 
most promising neo-epitope candidates is a difficult and time-consuming task. 
By virtue of the underlying mutational processes, the genome architecture and 
accessibility as well as for functional reasons within the disease process, certain 
somatic mutations will be present in multiple patients while still being highly specific 
to the tumor (10, 11). This might open the way to supplement existing personalized 
cancer immune treatments approaches with precision treatment options. 
Analysis of neo-epitope candidates has been carried out for selected highly recurrent 
mutations occurring in known cancer-related genes (12, 13). Here we provide an 
unbiased, comprehensive study of neo-epitopes arising from recurrent mutations: we 
carefully screen large cohorts of cancer genomes for recurrent missense mutations, 
identify possible candidates for strongly binding neo-antigens in multiple HLA-1 alleles 
using MHC-I binding predictions, and finally rank these candidates according to the 
expected number of target patients. A couple of these candidates were tested for in-
vivo activity.
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Results
Recurrent Variants and Neo-Epitopes
From the GDC repository (14), we have collected somatic variants for 33 TGCA studies.
After removing patients without clinical meta-data, and studies with less than 100 
patients, we have selected 1,384,531 high-confidence missense SNPs from 9,641 
patients, see methods for details. Using this data, 1,055 variants are deemed recurrent
(supplementary table 1), as they can be found in more than 1% of the patients in the 
respective study cohort. These recurrent variants correspond to 869 unique protein 
changes, as some appear in multiple cancer entities. 77 of the recurrent variants occur
in at least 3% of their cohort (43 unique protein changes). 
From these 869 unique protein changes, we have generated neo-epitope candidates 
that are predicted to be strong MHC class I binders in at least one of the 11 frequent 
HLA-1 types that we considered for initial selection. 415 (48%) of them lead to a 
strong binder prediction. In total, there are 772 candidates that are recurrent in a 
cancer entity cohort, and predicted as binding for a considered HLA-1 type. These 
candidates are unique among all the 9-, 10- & 11-mers containing the variant: the 
selection process retains only the peptide sequence with the lowest predicted IC50. 
Figure 1 and table 1 provide an overview of the variant selection and neo-epitope 
candidates generation processes, while supplementary table 2 lists all neo-epitopes 
(weak and strong predicted binders) after removing redundancy.
Despite large differences between variant filtering protocols, there is notable overlap 
between variants deemed recurrent by the above process, and variants identified in 
the cancer hotspot datasets (10) (supplementary figure 1). This overlap is strongly 
dependent on how frequent those variants are observed: there are 54 common 
variants out of the 61 variants observed more than 10 times over the whole dataset 
(>88%). Among the 819 retained variants (see methods), only 5 appear among the 
variants flagged as possible false positive by Chang et al. (<1%).
Confirmation of known cancer neo-epitopes
To validate our selection mechanism we aggregated two studies (15, 16) which collect 
reports of spontaneous CD8+ T-cell responses in cancer patients in whom the target 
epitopes were subsequently discovered. Both sets together (supplementary table 3) 
contain 37 epitopes, 35 of which could be mapped to an ENSEMBL transcript (33 
unique genes). For 27 of these epitopes our pipeline predicted strong binding with the 
specific HLA-1 type reported in the corresponding wet-lab investigations. Another 5 
epitopes where predicted as weak binders, some of the latter are also predicted to be 
strong binders in other HLA-1 types. Our pipeline classified 70% of a set of known 
tumor neo-antigens as strong binders and another 14% as weak binders. Therefore we
may assume that these 70% provide a rough estimate of the sensitivity of the 
screening. However we expect sensitivity to vary widely for different HLA-1 types due 
to the different amount of training data and resulting limitation of prediction 
performance in less frequent HLA-1 types. 
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4 out of 34 unique identifiable variants studied by van Buuren et al (16) and Fritsch 
(15) are found among our set of high confidence missense variants. CDK12:E928K 
occurs in one out of 530 Uterine Carcinoma donors, LPGAT1:D266N in one out of 985 
Breast carcinoma donors, and CDK4:R24C occurs in 1 out of 467 of melanoma-
patients. None of these epitopes have been assessed in our analysis, as their 
recurrence is below the 1% threshold. Only CTNNB1:S37F fulfills the 1% recurrence 
threshold (9 uterine carcinoma patients), and the peptide is predicted to be a strong 
binder for HLA-C*07:02. A longer peptide is predicted to be a strong binder for HLA-
B*15:01. 
The CDK4:R24C peptide (sequence ACDPHSGHFV, see supplementary table 1) is not 
predicted to bind to HLA-A*02:01, even tough it leads to confirmed T cell response 
(17), and has been related to cutaneous malignant melanoma and hereditary 
cutaneous melanoma (18, 19). Therefore the list of recurrent amino acids exchanges 
for which no binding epitopes are predicted might still be a valuable resource for 
future research, see supplementary tables 1 (all recurrent variants) and 2 (includes 
candidates predicted as weak binders). 
Enrichment in known cancer related genes
We observe that recurrent neo-epitope candidates are substantially enriched in known 
cancer-related genes (figure 1C). Initially approximatively one percent of all observed 
variants are found in genes that have been described (20, 21) as oncogenes or tumor 
suppressor genes. When recurrent unique protein changes are considered, the fraction
of known oncogenes or tumor suppressor genes is substantially increased to 13% and 
6.5% respectively. These fractions only marginally increase to 14% and 7% when only 
the unique protein changes leading to predicted strong binders for our 11 HLA-1 types 
are considered. Supplementary table 4 shows a similar enrichment of known cancer-
related genes per cohort. We observe that the enrichment is stronger for oncogenes 
than for tumor suppressors. This might be expected, as activating mutations in 
oncogenes are mainly distributed on a few protein positions, while loss of function 
mutations in tumor suppressors are generally distributed more broadly along the 
protein sequence.
It is interesting to observe that several of the highly prevalent neo-epitope candidates 
occur in genes that are involved in known immune escape mechanisms: RAC1:P29S is 
recurrent in study SKCM (melanoma), is predicted to lead to strong binding neo-
epitopes for HLA-A*01:01 and HLA-A*02:01, and is reported to up-regulate PD-L1 in 
melanoma (22). CTNNB1:S33C is recurrent in studies LIHC (liver hepatocellular 
carcinoma) and UCEC (uterine corpus endometrial carcinoma), is predicted to lead to 
strong binding neo-epitopes for HLA-A*02:01, and has been shown to increase the 
expression of the Wnt-signalling pathway in hepatocellular carcinoma (23), leading to 
modulation of the immune response (24) and ultimately to tumor immune escape (25).
In a separate study, Cho et al (26) show that this mutation confers acquired resistance
to the drug imatinib in metastatic melanoma. Finally, FLT3:D835Y recurrent in study 
LAML (acute myeloid leukemia), is predicted to lead to a strong binding neo-epitope 
for HLA-A*01:01, HLA-A*02:01 and HLA-C*06:02, and following Reiter et al. (27), 
Tyrosine Kinase Inhibitors promote the surface expression of the mutated FLT3, 
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enhancing FLT3-directed immunotherapy options, as its surface expression is 
negatively correlated with proliferation.
While the described mechanisms are probably sufficient to explain immune escape in 
tumor evolution, the candidates could nevertheless be viable targets for adoptive T 
cell therapy or TCR gene therapy.
Confirmation of MHC binding and T cell reactivity
In order to further test predicted epitopes for recognition in vivo we utilized transgenic 
mice that harbor the human TCRαβ gene loci, a chimeric HLA-A2 gene and are 
deficient for mouse TCRαβ and mouse MHC I genes (termed ABabDII). These mice 
have been shown to express a diverse human TCR repertoire (28, 29) and thus mimic 
human T cell response. Validation was carried out for candidate neo-epitopes 
RAC1:P29S & TRRAP:S722F (figure 2). ABabDII mice were immunized at least twice 
with mutant peptides and IFNγ producing CD8+ T cells were monitored in ex vivo ICS 
analysis 7 days after the last immunization. CD8+ T cells were purified from spleen 
cell cultures of reactive mice using either IFNγ-capture or tetramer-guided FACSort. 
Sequencing of specific TCR α and β chain amplicons that were obtained by RACE-PCR 
revealed that this procedure yields an almost monoclonal CD8+ T cell population (not 
shown). In both cases, tested neo-antigen candidates lead to T cell reactivity, 
confirming not only predicted MHC binding by our pipeline but also immunogenicity in 
vivo in human TCR transgenic mice. Therefore this workflow also allows to generate 
potentially therapeutic relevant TCRs to be used in the clinics for cancer 
immunotherapy.
Recurrent neo-epitopes in patient populations
Upon assumption of statistical independence, the product of the frequency of a 
recurrent neo-epitope with the frequency of class I alleles in the population and the 
incidence rates of cancer types provides an estimate for the number of patients that 
carry that specific neo-epitope. Using the number of newly diagnosed patients per 
year and HLA-1 frequency in the US population, we are able to compute the expected 
number of patients for 18 cancer entities for which both cancer census data and a 
TCGA study are available. The occurrence numbers for individual neo-epitope 
candidates range from 0 to 2,254 for PIK3CA:H1047R in breast cancer patients of type 
HLA-C*07:01; table 2 presents a summary of expected patient numbers for the 
complete set of candidates . We estimate that the previously discussed RAC1:P29S is 
present in 628 patients with the HLA-A*02:01 allele per year in the US alone: in 556 
melanoma patients and in 72 lung small cell, head & neck or uterine carcinomas 
patients (see supplementary table 5 for details). For the CTNNB1:S33C variant, the 
total number of HLA-A*02:01 patients in the US is expected to be 364, from uterine 
corpus, prostate and liver cancer types. As another example, 115 myeloid leukemia 
patients in the US are expected to be of type HLA-A*02:01 and harbor the FLT3:D835Y 
variant. 
Figure 3 shows the cumulative expected number of patients that carry a specific 
epitope, and with matching HLA-1 type, for the 50 candidates with the highest 
expected patients number. The number of patients is derived from the sum over all 
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cancer entities, including those in which the candidate is not recurrent according to 
our criteria. For example, among newly diagnosed patients of type HLA-C*04:02, 88 
prostate cancer patients are expected to carry the mutation PIK3CA:R88Q, even 
though its observed frequency in the PRAD study is as low as 0.2%. 
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Discussion 
Using existing cancer studies and neo-epitope binding predictions to MHC class I 
proteins, we propose a ranking of neo-epitopes that occur frequently in observed 
cancer patient cohorts, and that are potentially accessible to T cell immunotherapy 
treatments. This ranking is based on the expected number of patients of a particular 
HLA-1 type, who carry the recurrent mutation.
Despite numerous mechanisms of immune evasion, neo-epitopes are important 
targets of endogenous immunity (30): in some cases at least, it has been shown that 
they contribute to tumor recognition (31), achieve high objective response (in 
melanoma, 32), and a single of them is presumably sufficient for tumor regression 
(33). Moreover, positive association has been shown between antigen load and 
cytolytic activity (34), activated T cells (35) and high levels of the PD-1 ligand (36). 
Taken together, these results suggest that neo-epitopes occupy a central role in 
regulating immune response to cancer, and that this role can be exploited for cancer 
immunotherapy.
Targeting neo-epitopes based on non-recurrent, “private” somatic variants requires 
isolation of TCRs for each individual patient, which is currently still challenging (37). 
However, successful application of treatments based on genetically engineered 
lymphocytes has already been shown for epitopes arising from unmutated proteins 
(“public” epitopes): the MART-1 and gp100 proteins have been targeted in melanoma 
cases (38), as these proteins are expressed in the tumor cells. In another trial, Robbins
et al. (39) have studied long-term follow-up of patients who were treated with TCR-
transduced T cells against NY-ESO-1, a protein whose expression is normally restricted 
to testis, but which is frequently aberrantly expressed in tumor cells. The authors show
that the treatment may be effective for some patients. These results show that 
immune treatments can be beneficial, even when the selected epitopes are not 
obtained from sequencing the patient's tumor, but originate from ”off-the-shelf” 
peptides, whose sequence is known prior to the sequencing of the patient's tumor. 
However, targeting such unmutated epitopes presents safety and efficacy concerns 
(2): the administration of T cells transduced with MART-1 specific T-cell receptor have 
led to fatal outcomes (40), and cross-reactivity of TCR against MAGE-A3 (a protein 
normally restricted to testis and placenta) caused cardiovascular toxicity (41). Neo-
epitopes based on recurrent somatic variants potentially alleviate such problems (as 
the target sequences are truly restricted to tumor cells), while retaining the benefits of
“public” epitopes, for example regarding regulatory hurdles.
The neo-epitope landscape is diverse and sparse (33), with few neo-epitopes that are 
both predicted strong binders and present in multiple patients. In their analysis, 
Hartmaier et al. (13) estimate that neo-epitopes suitable used for precision immuno-
therapy might be relevant for about 0.3% of the population, in broad agreement with 
this study. However, the absolute number of patients is still considerable, even for 
neo-epitopes arising from less frequent mutations (between 1 and 3% of the cohort).
Taking into account the fact that MHC binding is a necessary but not sufficient 
condition for T cell activity, and the limitations of MHC binding prediction algorithms, 
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we provide an objective ranking of neo-epitopes based on recurrent variants, as a 
basis for the development of off-the-shelf immunotherapy treatments. We 
experimentally confirm T cell reactivity, thus immunogenicity, for a couple of these 
neo-epitopes.
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Methods
Data Sets
Somatic variants for different cancer entities have been determined using matched 
pairs of tumor and blood whole exome or whole genome sequencing in the TCGA 
consortium. We downloaded the open-access somatic variants from GDC data release 
7.0, consisting of 33 TCGA projects and 10,182 donors in total from (14). We excluded 
patients without corresponding entries in the clinical information tables, and 7 projects
with less than 100 samples, yielding 9,641 samples covering 26 cancer studies. 
Variant Selection
For each sample we selected all single nucleotide variants obtained by the “mutect2” 
pipeline, that had a “Variant_Type” equal to “SNP”, a valid ENSEMBL transcript ID and 
a valid protein mutation in “HGVSp_Short”. From these variants, we selected those 
with a “Variant_Classification” equal to “Missense_Mutation”. We checked that all 
variants had a “Mutation_Status” equal to (up to capitalisation) “Somatic”, that the 
total depth “t_depth” was the sum of the reference “t_ref_count” and the alternate 
“t_alt_count” alleles counts, and that the genomics variant length is one nucleotide. To
avoid high number of false positives we consider only variants that are supported by 
at least 5 reads and have a VAF of at least 10%. Furthermore we removed any variant 
that occurs with more than 1% in any population contained in the ExAC database 
version 0.31 (42), by coordinates liftover from the GRCh38 to hg19 human genome 
versions. This way we obtained 26 cancer entity data sets containing a total of 9,641 
samples with an overall 1,384,531 variants. 
Recurrent Protein Variant Filtering 
We define recurrence strictly on the protein/amino acid exchange level, i.e. different 
nucleotide acid variants leading to the same amino acid exchange due to code 
redundancy will be counted together. Recurrent protein variants are defined within 
each TCGA study. A protein variant is deemed recurrent when it appears in at least 1% 
of all the patients in the cohort. As cancer types are only considered when the number 
of patients involved in the studies is greater than 100, this threshold ensures that 
every recurrent variant has been observed in at least 2 patients for a given cancer 
type. To be conservative, the recurrence frequency has been computed using, for the 
denominator, all patients with clinical information in the study, including those without
high-confidence missense SNVs. Using this definition, the total number of recurrent 
amino acid changes is 1,055. A variant recurrent in multiple cancer types is counted 
multiple times in the above number, the number of unique recurrent variants 
regardless of the cancer is 869. Supplementary table 1 shows the most frequent amino
acid exchanges across 25 cancer entities, as no variant from project TCGA-KIRC's 
donors is labeled as recurrent. 
Recurrent variants occurring at the same positions (for example when gene's IDH1 
codon R132 is mutated to amino acid H, C, G or S) have been merged into 819 
variants suitable for comparisons with the cancer hot spots lists (10). 122 out of the 
819 merged variants belong to the set of 470 cancer hotspot variants, and 5 
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(PCBP1:L100, SPTLC3:R97, EEF1A1:T432, BCLAF1:E163 & TTN:S3271) to the set of 
presumptive false positives hotspots listed in the supplementary material of (10).
Epitopes Selection and MHC Class I Binding Prediction
In the next step all peptide stretches (9-, 10, or 11-mers) containing any of the 
identified recurrent amino acid exchanges are generated in silico. For MHC class I 
binding prediction we selected 11 frequent HLA-1 types: HLA-A*02:01, HLA-A*03:01, 
HLA-A*11:01, HLA-B*07:02, HLA-B*15:01, HLA-C*04:01, HLA-C*07:02, HLA-A*01:01, 
HLA-B*08:01, HLA-C*06:02, HLA-C*07:01. We predicted the MHC class I binding using 
NetMHCcons (43) v1.1, which predicts peptides IC50 binding, and classifies these 
predictions as non-binder, weak and strong binders. In the study, we have used these 
classes to filter our neo-epitope candidate. 
For a given recurrent variant and a given HLA-1 type, the epitope prediction pipeline 
can produce multiple overlapping epitopes candidates, differing only by their length. 
To remove such size redundancy, only the epitope with the lowest predicted mutant 
sequence IC50 is retained. This procedure also removes non-overlapping epitopes, to 
keep only at most one epitope per recurrent protein variant, cancer type and HLA-1 
type. For comparison we also compute the IC50 for the respective wild type peptide.
This way, we obtain 769 strong binding recurrent peptides and 1829 weak binders. 
Their complete list is in supplementary table 2, where each candidate is listed with the
HLA-1 type it is preticted to bind to.
Data QC
To ensure that the proportion of variants caused by technical artifacts is small, we 
have computed the proportion of SNVs called in poly-A, poly-C, poly-G or poly-T 
repeats of length greater than 6 have been computed for each data study (44), for 
unique variants (that occur in only one patient across a project cohort), and for 
variants that are observed more than once in a cohort (supplementary figure 1). For 
comparison, we have computed the expected frequency of such events, assuming that
all possible 11-mers (the mutated nucleotide at the center, flanked by 5 nucleotides on
each side) are equiprobable, regardless of their sequence. 
Generation of mutation-specific T cells in ABabDII mice 
For immunisation 8-12-week old ABabDII mice were injected subcutaneously with 100 
μg of mutant short peptide (9-10mers, JPT) supplemented with 50 μg CpG 1826 (TIB 
Molbiol), emulsified in incomplete Freund’s adjuvant (Sigma). Repetitive immunizations
were performed with the same mixture at least three weeks apart. Mutation-specific 
CD8+ T cells in the peripheral blood of immunized animals were assessed by 
intracellular cytokine staining (ICS) for IFNγ 7 days after each boost. All animal 
experiments were performed according to institutional and national guidelines and 
regulations after approval by the governmental authority (Landesamt für Gesundheit 
und Soziales, Berlin).
Patient Number Estimates and HLA-1 Frequencies 
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HLA-1 frequency data f for the U.S. population was retrieved from the Allele Frequency 
Net Database (AFND) (45). Frequency data were estimated by averaging the allele 
frequencies* of multiple population datasets from the North American (NAM) 
geographical region. The major U.S. ethnic groups were included and sampled under 
the NAM category.
Cancer incidence data for the U.S. population (Nd) was retrieved from the GLOBOCAN 
2012 project of the International Agency for Research on Cancer, WHO (46).
We assume that the fraction of a recurrent variant in the U.S. population affected by 
cancer entity d (rd) is identical to the observed ratio of that variant in the 
corresponding TCGA study. 
Given a variant leading to a neo-epitope predicted to be binding strongly to MHC class 
I proteins of HLA-1 type h, the number of patients of HLA-1 type h whose tumor 
contain that variant is expected to be
nh=f h∑
d
rd Nd
The summation runs over 18 diseases d for which both the TCGA projects and the 
cancer incidence data are available.
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Figure 1: (A) Overview of the recurrent neo-epitope candidates generation process: TCGA studies are selected
for at least 100 donors with clinical annotations. For each of these studies, recurrent strongly supported missense
Single-Nucleotide Variants are collected. Neo-epitopes binding to 11 HLA-1 types are predicted, redundancy is
removed from that set (see B) and strong binders are retained. (B) Example of epitope redundancy: the 18
amino-acids long sequence surrounding recurrent variant GLRA3:S274L generates 7 binding neo-epitopes for
the type HLA-A*02:01. Our pipeline retains only the strongest predicted binder for a given variant and HLA-1 type
pair (the first, with an IC50 of 8.8 nM in the example). (C) Number of SNVs classified as Oncogenes or Tumor
Suppressors by Vogelstein et al. (20), at various point of the variant selection and neo-epitope filtering process.
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Figure 2: Recognition of predicted epitopes by CD8+ T cells: Epitopes for recurrent mutations that have been
identified in silico to bind to HLA-A*02:01 using our pipeline were synthesized and used for immunization of
human TCR transgenic ABabDII mice. Examples (RAC1:P29S and TRRAP:S722F) of ex vivo ICS analysis of
mutant peptide immunized ABabDII mice 7 days after the last immunization are shown. Polyclonal stimulation
with CD3/CD28 dynabeads was used as positive control, stimulation with an irrelevant peptide served as negative
control (data not shown).
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TCGA study has been included in our analysis.
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